Your browser doesn't support javascript.
loading
Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial.
Newsome, Philip Noel; Fox, Richard; King, Andrew L; Barton, Darren; Than, Nwe-Ni; Moore, Joanna; Corbett, Christopher; Townsend, Sarah; Thomas, James; Guo, Kathy; Hull, Diana; Beard, Heather A; Thompson, Jacqui; Atkinson, Anne; Bienek, Carol; McGowan, Neil; Guha, Neil; Campbell, John; Hollyman, Dan; Stocken, Deborah; Yap, Christina; Forbes, Stuart John.
Afiliación
  • Newsome PN; National Institute for Health Research Liver Biomedical Research Unit, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; Centre for Liver Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Liver Unit, Un
  • Fox R; National Institute for Health Research Liver Biomedical Research Unit, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; University of Birmingham, NIHR Liver BRU Clinical trials group, Cancer Research UK Clinical Trials Unit, Birmingham, UK.
  • King AL; National Institute for Health Research Liver Biomedical Research Unit, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; Centre for Liver Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Liver Unit, Un
  • Barton D; National Institute for Health Research Liver Biomedical Research Unit, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; University of Birmingham, NIHR Liver BRU Clinical trials group, Cancer Research UK Clinical Trials Unit, Birmingham, UK.
  • Than NN; National Institute for Health Research Liver Biomedical Research Unit, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; Centre for Liver Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Liver Unit, Un
  • Moore J; Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK.
  • Corbett C; National Institute for Health Research Liver Biomedical Research Unit, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK.
  • Townsend S; National Institute for Health Research Liver Biomedical Research Unit, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Thomas J; Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK.
  • Guo K; National Institute for Health Research Liver Biomedical Research Unit, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; Centre for Liver Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Hull D; National Institute for Health Research Liver Biomedical Research Unit, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; Centre for Liver Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Beard HA; National Institute for Health Research Liver Biomedical Research Unit, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; Cellular and Molecular Therapies, NHSBlood and Transplant, Birmingham, UK.
  • Thompson J; Cellular and Molecular Therapies, NHSBlood and Transplant, Birmingham, UK.
  • Atkinson A; Scottish National Blood Transfusion Service, Edinburgh, UK.
  • Bienek C; Scottish National Blood Transfusion Service, Edinburgh, UK.
  • McGowan N; Scottish National Blood Transfusion Service, Edinburgh, UK.
  • Guha N; National Institute for Health Research Biomedical Research Unit in Gastrointestinal and Liver Diseases, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
  • Campbell J; Scottish National Blood Transfusion Service, Edinburgh, UK.
  • Hollyman D; Cellular and Molecular Therapies, NHSBlood and Transplant, Birmingham, UK.
  • Stocken D; Newcastle University, Newcastle Clinical Trial Unit, Institute of Health and Society, Newcastle, UK.
  • Yap C; University of Birmingham, NIHR Liver BRU Clinical trials group, Cancer Research UK Clinical Trials Unit, Birmingham, UK.
  • Forbes SJ; Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK.
Lancet Gastroenterol Hepatol ; 3(1): 25-36, 2018 01.
Article en En | MEDLINE | ID: mdl-29127060
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factor Estimulante de Colonias de Granulocitos / Trasplante de Células Madre Hematopoyéticas / Antígeno AC133 / Cirrosis Hepática Tipo de estudio: Clinical_trials Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Gastroenterol Hepatol Año: 2018 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factor Estimulante de Colonias de Granulocitos / Trasplante de Células Madre Hematopoyéticas / Antígeno AC133 / Cirrosis Hepática Tipo de estudio: Clinical_trials Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Gastroenterol Hepatol Año: 2018 Tipo del documento: Article Pais de publicación: Países Bajos